Oral etoposide in relapsed or refractory Ewing sarcoma: a monoinstitutional experience in children and adolescents.


AIMS To assess the efficacy and toxicity of low-dose oral etoposide (VP) 16 in relapsing/refractory Ewing sarcoma. METHODS The records of all patients treated at our department between 1989 and 2012 for relapsing/refractory Ewing sarcoma who received oral VP-16 were analyzed. The dose was 40 mg/m2 daily for 21 consecutive days in every 28. Response was… (More)
DOI: 10.5301/tj.5000419


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics